Portal hypertension medical therapy: Difference between revisions
Created page with "__NOTOC__ {{Portal hypertension}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. ==Overview== Treat..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | |||
{{Portal hypertension}} | {{Portal hypertension}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[help:How to Edit a Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[help:How to Edit a Page|here]] to learn about editing. | ||
Revision as of 15:21, 16 April 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Portal Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Portal hypertension medical therapy On the Web |
|
American Roentgen Ray Society Images of Portal hypertension medical therapy |
|
Risk calculators and risk factors for Portal hypertension medical therapy |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Treatment with a non-selective beta blocker is often commenced once portal hypertension has been diagnosed, and almost always if there has already been bleeding from esophageal varices. Typically, this is done with either propranolol or nadolol. The addition of a nitrate, such as isosorbide mononitrate, to the beta blocker is more effective than using beta blockers alone and may be the preferred regimen in those people with portal hypertension who have already experienced variceal bleeding. In acute or severe complications of the hypertension, such as bleeding varices, intravenous octreotide (a somatostatin analogue) or intravenous terlipressin (an antidiuretic hormone analogue) is commenced to decrease the portal pressure.